Darwin Molecular Corporation
Records under this name other than patents Darwin Molecular Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Darwin Molecular Corporation
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,381,409 | Antibodies specific for sclerostin and methods of screening and use therefor Formerly held Term ended Term ended Jul 1, 2025 · High confidence | Term ended | Term ended Jul 1, 2025 | High confidence |
| US 11,702,468 | Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization Formerly held Term ended Term ended Sep 18, 2024 · Medium confidence | Term ended | Term ended Sep 18, 2024 | Medium confidence |
| US 9,657,095 | Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization Formerly held Term ended Ended no later than Jun 16, 2024 · Medium confidence | Term ended | Ended no later than Jun 16, 2024 | Medium confidence |
| US 7,868,134 | Immunogenic Peptides Derived from Sclerostin Formerly held Term ended Ended no later than Jun 15, 2024 · Medium confidence | Term ended | Ended no later than Jun 15, 2024 | Medium confidence |
| US 8,563,271 | Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization Formerly held Term ended Term ended Jun 15, 2024 · High confidence | Term ended | Term ended Jun 15, 2024 | High confidence |
| US 8,992,911 | Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization Formerly held Term ended Ended no later than Jun 15, 2024 · Low confidence | Term ended | Ended no later than Jun 15, 2024 | Low confidence |
| US 9,011,856 | Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization Formerly held Term ended Ended no later than Jun 15, 2024 · Medium confidence | Term ended | Ended no later than Jun 15, 2024 | Medium confidence |
| US 7,572,899 | Compositions and methods for increasing bone mineralization Formerly held Term ended Term ended Dec 24, 2020 · USPTO record | Term ended | Term ended Dec 24, 2020 | USPTO record |
| US 7,578,999 | Antibodies Specific for Sclerostin Formerly held Term ended Ended no later than Jul 4, 2020 · Low confidence | Term ended | Ended no later than Jul 4, 2020 | Low confidence |
| US 7,192,583 | Methods for modulating bone mineralization Formerly held Term ended Term ended Feb 6, 2020 · USPTO record | Term ended | Term ended Feb 6, 2020 | USPTO record |